LAWRENCE, KS - (03/10/2021) - Clara Biotech, Inc, a Kansas City based biotechnology company developing its ExoRelease™ immunocapture and release platform to isolate and purify exosomes, today announced a newly appointed board director and members of its Advisory Board.
The Advisory Board comprises business leaders with extensive experience in leadership and strategic advisory roles for biotech and early-stage companies with expertise in lab tools, diagnostics, and therapeutics.
Joseph Gentile has been a member of the advisory board since 2020 and was recently appointed to Clara Biotech’s Board of Directors. He brings a wealth of experience and expertise in medical devices, diagnostics, and life science tools and is an active advisor to numerous biotechnology startups.
Michael Singer, MD, PhD is co-founder and Chief Scientific Officer of Cartesian Therapeutics, and an Assistant Professor of Medicine at Yale University. Dr. Singer serves as a board member of numerous therapeutic and biotech companies.
Martin Madaus, DVM, PhD is the former CEO of Roche Diagnostics and Milipore and has held numerous top leadership positions in bioscience firms. He has a broad range of experience in the biotechnology industry including life science research products and biotechnology products and services. Dr. Madaus currently serves as a board member, strategic advisor, and investor in multiple biotechnology companies.
Rick Ryan, PhD, MBA is a General Partner at the venture firm Cultivation Capital Life Sciences. Rick’s career spans forty years in the life science industry, with executive management roles in both R&D and General Management. He has deep experience in research tools/reagents and pharmaceutical development in both multinational corporations and early-stage private ventures. He serves on several boards and strategic advisory positions for early-stage ventures.
About Clara Biotech
Clara Biotech was founded in 2018 by Dr. Mei He, an exosome researcher and assistant professor at the University of Florida, and James E West III, engineer, and entrepreneur. Clara Biotech has developed novel methods to isolate and purify exosomes. Its non-chemical ExoRelease™ platform uses proprietary immunocapture and release technology to exclusively isolate exosomes. The ExoRelease™ platform provides a simple, reproducible, time-saving protocol and has the same process for multiple bio-sample types. This yields pure, completely functional, in-tact, and subtyped exosomes. Clara Biotech is commercializing an ExoRelease™ lab kit for Research Use Only